Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
AbbVie to Acquire Pharmacyclics, including its blockbuster product Imbruvica, Creating an Industry Leading Hematological Oncology Franchise. Under the terms of…
AbbVie Acquires Oncology Drug Firm Pharmacyclics for $21 Billion.
Imbruvica projected at $14B peak sales with 85% reduction in death risk in CLL trials. Whether it offsets Humira risk still remains to be seen.
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
AbbVie acquired Pharmacyclics for approximately $21 billion ($261.25 per share in a 58% cash / 42% stock mix), gaining full ownership of Imbruvica (ibrutinib), a first-in-class BTK inhibitor with four approved indications in hematologic malignancies and over 50 ongoing clinical studies.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Pharmacyclics Inc. (this deal) | 2015 | $21.0B | 79 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
| AbbVie Inc. / MedinCell S.A. | 2024 | $1.9B | 61 |
← Browse all deals · How we score deals
More: 2015 deals · AbbVie Inc. deals · Hematology deals